Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
Intel Stock Surges as AI Chip Demand Drives Strong Q2 Forecast 
Judge Dismisses Elon Musk’s Fraud Claims Against OpenAI, Trial to Proceed on Remaining Allegations 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
$16B Michigan Data Center Project Boosts U.S. AI Infrastructure Expansion 
Kakaku.com Stock Surges on EQT Takeover Interest Amid Rising Japan Deal Activity 
DeepSeek Launches V4 AI Models with Enhanced Reasoning and 1M Token Context Window 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
Organon Stock Surges After Reports of $13 Billion Buyout Bid by Sun Pharma 
Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules 
Amazon Stock Rises as Meta Expands AWS Partnership for AI Infrastructure 
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review 
U.S. Raises Alarm Over Chinese AI Firms’ Alleged IP Theft Through Model Distillation 
Why Global Web3 Projects Can't Afford to Skip South Korea: TokenPost Unveils Data-Driven Entry Solutions 
Heidelberg, Germany, May 17, 2017 - Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, announced today that data for Affimed's preclinical AFM24 and AFM26 programs will be presented at the American Society of Clinical Oncology (ASCO) 2017 Annual Meeting being held June 2 - 6, 2017 in Chicago, IL and at the EACR-AACR-SIC Special Conference 2017 being held June 24 - 27, 2017 in Florence, Italy, respectively.
ASCO 2017 Annual Meeting
AFM26 (poster)
Abstract: AFM26 is a novel, highly potent BCMA/CD16A-directed bispecific antibody for high affinity NK-cell engagement in multiple myeloma (#8045)
Poster: Monday, June 5, 2017 8:00 AM-11:30 AM CST, Session Hematologic Malignancies
AFM24 (abstract only)
Abstract: EGFR/CD16A tetravalent bispecific antibody AFM24 to engage NK-cells to kill EGFR expressing tumor cells and safety results in cynomolgus monkey studies. (#e14001)
Online Publication: Wednesday, May 17, 2017, 5:00 PM EDT
Full abstracts can be accessed on the ASCO website at abstracts.asco.org.
EACR-AACR-SIC Special Conference 2017
AFM26 (poster)
Abstract: AFM26: A first-in-class, high affinity bispecific NK-cell engager targeting BCMA to treat multiple myeloma
Poster: #575, Monday, June 26, 2017, 10:15 AM-5:00 PM CET, Session "Tumour Immunology II"
AFM24 (poster)
Abstract: High affinity bispecific EGFR/CD16A antibodies specifically recruit NK-cells to target EGFR-expressing tumors
Poster: #574, Monday, June 26, 2017, 10:15 AM-5:00 PM CET, Session "Tumour Immunology II"
Abstracts to be released June 23, 2017.
About Affimed N.V.
Affimed (Nasdaq: AFMD) engineers targeted immunotherapies, seeking to cure patients by harnessing the power of innate and adaptive immunity (NK- and T-cells). We are developing single and combination therapies to treat cancers and other life-threatening diseases. For more information, please visit www.affimed.com.
IR Contact:
Caroline Stewart, Head IR
Phone: +1 347394 6793
E-Mail: [email protected] or [email protected]
Media Contact:
Anca Alexandru, Head of Communications
Phone: +49 6221 64793341
E-Mail: [email protected]
